Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

We hypothesized that the combination of olaparib and lurbinectedin maximizes DNA damage, thus increasing its efficacy. The POLA phase 1 trial established the recommended phase 2 dose of lurbinectedin as being 1.5 mg (day 1) and that of olaparib as being 250 mg/12 h (days 1–5) for a 21-day cycle. In...

Full description

Bibliographic Details
Main Authors: Andres Poveda, Raquel Lopez-Reig, Ana Oaknin, Andres Redondo, Maria Jesus Rubio, Eva Guerra, Lorena Fariñas-Madrid, Alejandro Gallego, Victor Rodriguez-Freixinos, Antonio Fernandez-Serra, Oscar Juan, Ignacio Romero, Jose A. Lopez-Guerrero
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
ovarian cancer
endometrial cancer
lurbinectedin
olaparib
genomic instability
Online Access:https://www.mdpi.com/2072-6694/14/4/915

Internet

https://www.mdpi.com/2072-6694/14/4/915

Similar Items